SS
CRSP icon

Sunbelt Securities’s CRISPR Therapeutics CRSP Stock Holding History

Sunbelt Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$373K Buy
7,843
+336
+4% +$17.7K 0.02% 474
2025
Q4 		$394K Hold
7,507
– – 0.03% 460
2025
Q3 		$487K Buy
7,507
+1,342
+22% +$77K 0.03% 397
2025
Q2 		$243K Sell
6,165
-625
-9% -$24.2K 0.02% 543
2025
Q1 		$231K Buy
6,790
+625
+10% +$26.5K 0.02% 531
2024
Q4 		$238K Buy
6,165
+3,210
+109% +$152K 0.02% 548
2024
Q3 		$139K Buy
2,955
+300
+11% +$15.2K 0.01% 683
2024
Q2 		$143K Buy
2,655
+500
+23% +$28.9K 0.01% 654
2024
Q1 		$147K Hold
2,155
– – 0.02% 620
2023
Q4 		$135K Hold
2,155
– – 0.02% 594
2023
Q3 		$97.8K Hold
2,155
– – 0.01% 658
2023
Q2 		$121K Hold
2,155
– – 0.02% 591
2023
Q1 		$95.2K Buy
+2,155
New +$105K 0.02% 594

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sunbelt Securities's CRSP Position: Q1 2026 in Review

Sunbelt Securities increased its CRISPR Therapeutics (CRSP) stake by 4.5% in Q1 2026, buying an estimated $17.7K and bringing the position to 7,843 shares worth $373K. The position accounts for 0.02% of the portfolio, ranked #474.

Sunbelt Securities first reported a position in CRSP in Q1 2023 and has held it in 13 quarters since. The position peaked at $487K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Sunbelt Securities held 7,843 shares of CRISPR Therapeutics worth $373K as of Q1 2026.
  • Sunbelt Securities bought 336 CRISPR Therapeutics shares in Q1 2026, an estimated $17.7K.
  • CRISPR Therapeutics made up 0.02% of Sunbelt Securities's portfolio in Q1 2026, its #474 holding.
  • Sunbelt Securities first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Sunbelt Securities's CRISPR Therapeutics position peaked at $487K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.